Joanne Yacobovich

Dr. Joanne Yacobovich

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Blood
Verified
Journal Article
Open access
PDF file
AZAdi Zoref-Lorenz
Adi Zoref-Lorenz
JMJun Murakami
Jun Murakami
LHLiron Hofstetter
Liron Hofstetter
SISwaminathan Iyer
Swaminathan Iyer
AAAhmad S. Alotaibi
Ahmad S. Alotaibi
MJMichael B. Jordan
Michael B. Jordan
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening inflammatory syndrome that may complicate hematologic malignancies (HMs). The appropriateness of current criteria for diagnosing HLH in the context of HMs is unknown because they were developed for children with familial HLH (HLH-2004) or derived from adult patient cohorts in which HMs were underrepresented (HScore). Moreover, many features of these criteria may directly reflect the underlying HM rather than an abnormal inflammatory state. To improve and potentially simplify HLH diagnosis in patients with HMs, we studied an international cohort of 225 adult patients with various HMs both with and without HLH and for whom HLH-2004 criteria were available. Classification and regression tree and receiver-operating curve analyses were used to identify the most useful diagnostic and prognostic parameters and to optimize laboratory cutoff values. Combined elevation of soluble CD25 (>3900 U/mL) and ferritin (>1000 ng/mL) best identified HLH-2004–defining features (sensitivity, 84%; specificity, 81%). Moreover, this combination, which we term the optimized HLH inflammatory (OHI) index, was highly predictive of mortality (hazard ratio, 4.3; 95% confidence interval, 3.0-6.2) across diverse HMs. Furthermore, the OHI index identified a large group of patients with high mortality risk who were not defined as having HLH according to HLH-2004/HScore. Finally, the OHI index shows diagnostic and prognostic value when used for routine surveillance of patients with newly diagnosed HMs as well as those with clinically suspected HLH. Thus, we conclude that the OHI index identifies patients with HM and an inflammatory state associated with a high mortality risk and warrants further prospective validation.

7 March 2024 in Blood
Verified
Journal Article
Closed access
PDF file
SBSvea Böhm
Svea Böhm
KWKatharina Wustrau
Katharina Wustrau
JSJana Pachlopnik Schmid
Jana Pachlopnik Schmid
SPSeraina Prader
Seraina Prader
MAMartina Ahlmann
Martina Ahlmann
SEStephan Ehl
Stephan Ehl
Primary hemophagocytic lymphohistiocytosis (pHLH) is a life-threatening hyperinflammatory syndrome that develops mainly in patients with genetic disorders of lymphocyte cytotoxicity and X-linked lymphoproliferative syndromes. Previous studies with etoposide-based treatment followed by hematopoetic stem cell transplantation (HSCT) resulted in 5-year survival of 50% to 59%. Contemporary data are lacking. We evaluated 88 patients with pHLH documented in the international HLH registry from 2016-2021. In 12 of 88 patients, diagnosis was made without HLH activity, based on siblings or albinism. Major HLH-directed drugs (etoposide, antithymocyte globulin, alemtuzumab, emapalumab, ruxolitinib) were administered to 66 of 76 patients who were symptomatic (86% first-line etoposide); 16 of 57 patients treated with etoposide and 3 of 9 with other first-line treatment received salvage therapy. HSCT was performed in 75 patients; 7 patients died before HSCT. Three-year probability of survival (pSU) was 82% (confidence interval [CI], 72%-88%) for the entire cohort and 77% (CI, 64%-86%) for patients receiving first-line etoposide. Compared with the HLH-2004 study, both pre-HSCT and post-HSCT survival of patients receiving first-line etoposide improved, 83% to 91% and 70% to 88%. Differences to HLH-2004 included preferential use of reduced-toxicity conditioning and reduced time from diagnosis to HSCT (from 148 to 88 days). Three-year pSU was lower with haploidentical (4 of 9 patients [44%]) than with other donors (62 of 66 [94%]; P < .001). Importantly, early HSCT for patients who were asymptomatic resulted in 100% survival, emphasizing the potential benefit of newborn screening. This contemporary standard-of-care study of patients with pHLH reveals that first-line etoposide-based therapy is better than previously reported, providing a benchmark for novel treatment regimes.

1 November 2013 in The Journal of Pediatrics
Verified
Journal Article
Closed access
SRShoshana Revel-Vilk
Shoshana Revel-Vilk
JYJoanne Yacobovich
Joanne Yacobovich
SFShlomzion Frank
Shlomzion Frank
TBTal Ben-Ami
Tal Ben-Ami
MYMichal Yechieli
Michal Yechieli
HTHannah Tamary
Hannah Tamary

4 October 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ALAsaf Lebel
Asaf Lebel
JYJoanne Yacobovich
Joanne Yacobovich
TKTanya Krasnov
Tanya Krasnov
AKAriel Koren
Ariel Koren
CLCarina Levin
Carina Levin
HTHannah Tamary
Hannah Tamary

18 October 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
JYJoanne Yacobovich
Joanne Yacobovich
TBTal Ben‐Ami
Tal Ben‐Ami
TATameemi Abdalla
Tameemi Abdalla
HTHannah Tamary
Hannah Tamary
GGGal Goldstein
Gal Goldstein
SRShoshana Revel‐Vilk
Shoshana Revel‐Vilk

30 November 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
BVBethany Verkamp
Bethany Verkamp
AZAdi Zoref-Lorenz
Adi Zoref-Lorenz
BFBrenton Francisco
Brenton Francisco
PKPearce Kieser
Pearce Kieser
JMJoana Mack
Joana Mack
MJMichael B. Jordan
Michael B. Jordan
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that is most commonly treated with etoposide and dexamethasone. This standard of care therapy has improved survival, but ∼15% of patients still die in the first months after diagnosis, and poor responses prompting salvage therapy are frequent. Thus, identifying patients at risk promptly is likely to improve outcomes. We conducted a multi-institutional, retrospective study of pediatric and young adults treated per HLH-94 or HLH-2004 from 2010 to 2019 to identify patients at risk for early mortality. Biweekly data during the first 100 days of treatment were analyzed using receiver operating curves to define optimal prognostic indicators and their thresholds. The primary end point was survival to bone marrow transplant (BMT) or ∼1 year if no BMT was pursued. Eighty-nine patients met the study inclusion criteria. Pre-BMT mortality was 13% (n = 12), and overall mortality was 27% (n = 24). Laboratory markers measured on day 7 of therapy more efficiently predicted outcomes than did either pretreatment or later assessments. The most potent day 7 unfavorable marker was improvement in soluble CD25 (sCD25) of less than 25% from pretherapy levels. Absolute sCD25 level, platelet count, absolute lymphocyte count, and blood urea nitrogen were also discriminatory markers (area under the curve ≥ 0.7). The presence of ≥3 of these unfavorable markers was strongly associated with pre-BMT mortality (accuracy, 0.93). Thus, serial monitoring of sCD25 and assessment of other early (day 7) response markers optimally predicts prognosis with etoposide-based therapy and may indicate the need for earlier use of alternative, response-adapted therapeutic strategies for HLH.